Antegenes^® Men

• 121 genetic variants associated with prostate cancer
• 91 genetic variants associated with colorectal cancer
• 28 genetic variants associated with skin melanoma

A personalised results report will be sent to the customer and made available to their clinician* (upon the customers consent)**.

There are two possible result outcomes from this test:

1. A lower risk test result
2. An increased risk test result

Every person taking the test will be sent a clinical support video explaining what their test results mean and the next steps to take.

In the case of an increased risk result, guidance is provided on what the customer should do next. This may include talking to their clinician about earlier screening options to help reduce the risk of developing the cancers tested for or seeking treatment earlier to help prevent mortality from the disease.

The results report will include the following:

1. Polygenic risk score: A score derived from thousands of genetic variants.
2. Personal risk: This shows an individual’s risk of developing the cancer tested for over the next 10 years, compared to someone of their age in the general population.
3. General population comparison: A number showing the average risk that someone of a similar age in the general population has of developing prostate cancer.
4. Relative Risk: A number which compares your risk to that of the general population.

No personal medical guidance is provided in the test results report. This should be obtained from the customer’s clinician.

* Results reports are only sent to the customers clinician when a test is organised through a GP/clinic/hospital.
**No results information is shared with an employer or insurance provider.

Who can order this test from Everything Genetic? Healthcare providers, employers and individuals.

Turnaround time: 4 weeks from the receipt of a sample in our laboratory.

Preferred specimen: Non-invasive simple saliva sample using Oragene OG-610.

Alternative specimen collection: None.

Delivery information: Test kits will be sent out by using a Royal Mail Tracked service, unless otherwise arranged.

Pre and post-test clinical support is a mandatory requirement for all customers taking the test.

Pre-test support is provided through a clinically guided informational video which explains:

• What the test is for
• Why customers should take the test
• What it does and doesn’t test for
• What the possible results are from taking the test

Following the test, customers will be provided a further clinically guided information video, depending on their level of risk.

In the case of an increased risk result, guidance is provided on what the customer should do next. This may include talking to their clinician about earlier screening options to help reduce the risk of developing cancer or seeking treatment earlier to help prevent mortality from the disease.

For both pre and post-test clinical support, the customer has the option to arrange a telephone call with our Medical Director, Dr James Mackay.

Antegenes^® Men uses genome-wide single nucleotide polymorphisms (SNPs) to evaluate individual polygenic risks of developing prostate cancer, colorectal cancer and skin melanoma.

It combines three tests:

• Antegenes^® Prostate
• Antegenes^® Colorectal
• Antegenes^® Melanoma

Antegenes^® Prostate
The risk of developing hereditary prostate cancer is estimated at around 5%. However, there are over 160 prostate cancer risk-associated SNPs that have been identified through genetic studies. These can be used to determine the carrier status of genetic variants that affect a customer’s individual risk and are combined into a polygenic risk assessment, along with a 10-year probability of developing the disease.

Antegenes^® Colorectal
Colorectal cancer is the third most diagnosed cancer, and can be caused by pathogenic variants in MLH1, MSH2, MSH6, PMS2 and EPCAM.  However, there are over 91 genetic variants associated with colorectal cancer. Antegenes® Colorectal uses data from genome-wide single nucleotide polymorphisms (SNPs) to evaluate individual polygenic risks of developing colorectal cancer.

Antegenes^® Melanoma
The inherited risk of developing melanoma is considered low, with only around 8% of affected individuals having a first-degree relative with melanoma. However, individual melanoma risk can be very high, even if there is no family history.

When testing for the genetic risk of developing melanoma, we analyse a wide genome panel consisting of 28 genes associated with a hereditary predisposition to melanoma. These genes were selected based on available evidence to provide the most comprehensive test targeting for melanoma.

Antegenes^® Men is a registered CE-marked medical device (IVD) developed by the Antegenes Medical Laboratory.

Limitations:

• Antegenes^® Men test is not used to diagnose prostate cancer, colorectal cancer or skin melanoma.
• An increased risk estimated by the Antegenes^® Men test does not mean that the customer will develop prostate cancer, colorectal cancer or skin melanoma during their lifetime. Also, a lower risk does not mean that the probability of developing the diseases is zero.
• Antegenes^® Men test does not assess the risk of family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children.
• The test does not analyse rare pathogenic mutations in prostate, colorectal and melanoma genes that significantly increase the risk of developing the cancers.
• This genetic test is based on the most up-to-date scientific data, which may be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations.
• Different polygenic risk scores that predict risks of the same trait may provide different estimates. This is due to differences in genetic variants included in the models and their weights.
• The results of this test should be applied in context with other relevant clinical data, and other risk factors.

Validations and papers

View all validation documents and papers for this genetic test here >>